MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CIPLA - ASTRAZENECA PHARMA
CIPLA vs ASTRAZENECA PHARMA - Comparison Results
CIPLA 
Change
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
ASTRAZENECA PHARMA
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Current Valuations
| CIPLA | ASTRAZENECA PHARMA | CIPLA/ ASTRAZENECA PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 33.3 | 391.7 | 8.5% | View Chart |
| P/BV | x | 2.9 | 19.2 | 15.1% | View Chart |
| Dividend Yield | % | 0.6 | 0.0 | - |
Financials
 CIPLA  ASTRAZENECA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CIPLA Mar-18 |
ASTRAZENECA PHARMA Mar-14 |
CIPLA/ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 663 | 1,285 | 51.6% | |
| Low | Rs | 479 | 634 | 75.6% | |
| Sales per share (Unadj.) | Rs | 189.0 | 189.6 | 99.7% | |
| Earnings per share (Unadj.) | Rs | 17.6 | -0.2 | -8,641.7% | |
| Cash flow per share (Unadj.) | Rs | 34.0 | 3.8 | 885.0% | |
| Dividends per share (Unadj.) | Rs | 3.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.5 | 0 | - | |
| Book value per share (Unadj.) | Rs | 176.7 | 68.6 | 257.5% | |
| Shares outstanding (eoy) | m | 805.12 | 25.00 | 3,220.5% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 3.0 | 5.1 | 59.7% | |
| Avg P/E ratio | x | 32.5 | -4,712.7 | -0.7% | |
| P/CF ratio (eoy) | x | 16.8 | 249.6 | 6.7% | |
| Price / Book Value ratio | x | 3.2 | 14.0 | 23.1% | |
| Dividend payout | % | 17.1 | 0 | - | |
| Avg Mkt Cap | Rs m | 459,724 | 23,988 | 1,916.5% | |
| No. of employees | `000 | 23.6 | 1.6 | 1,514.4% | |
| Total wages/salary | Rs m | 26,901 | 1,605 | 1,676.5% | |
| Avg. sales/employee | Rs Th | 6,446.1 | 3,040.2 | 212.0% | |
| Avg. wages/employee | Rs Th | 1,139.4 | 1,029.2 | 110.7% | |
| Avg. net profit/employee | Rs Th | 600.0 | -3.3 | -18,376.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 152,193 | 4,740 | 3,211.0% | |
| Other income | Rs m | 3,577 | 92 | 3,883.3% | |
| Total revenues | Rs m | 155,769 | 4,832 | 3,223.8% | |
| Gross profit | Rs m | 28,264 | -130 | -21,774.9% | |
| Depreciation | Rs m | 13,228 | 101 | 13,071.3% | |
| Interest | Rs m | 1,142 | 0 | - | |
| Profit before tax | Rs m | 17,470 | -139 | -12,577.2% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | -28 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -775 | 139 | -558.1% | |
| Tax | Rs m | 2,501 | 5 | 49,137.5% | |
| Profit after tax | Rs m | 14,166 | -5 | -278,304.5% | |
| Gross profit margin | % | 18.6 | -2.7 | -678.1% | |
| Effective tax rate | % | 14.3 | -3.7 | -390.7% | |
| Net profit margin | % | 9.3 | -0.1 | -8,667.2% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 108,141 | 2,726 | 3,966.4% | |
| Current liabilities | Rs m | 38,322 | 2,435 | 1,573.8% | |
| Net working cap to sales | % | 45.9 | 6.1 | 746.2% | |
| Current ratio | x | 2.8 | 1.1 | 252.0% | |
| Inventory Days | Days | 97 | 74 | 131.5% | |
| Debtors Days | Days | 74 | 41 | 182.5% | |
| Net fixed assets | Rs m | 109,411 | 1,035 | 10,568.1% | |
| Share capital | Rs m | 1,610 | 50 | 3,220.4% | |
| "Free" reserves | Rs m | 140,682 | 942 | 14,928.0% | |
| Net worth | Rs m | 142,292 | 1,716 | 8,292.1% | |
| Long term debt | Rs m | 36,621 | 0 | - | |
| Total assets | Rs m | 228,606 | 4,156 | 5,500.6% | |
| Interest coverage | x | 16.3 | NM | - | |
| Debt to equity ratio | x | 0.3 | 0 | - | |
| Sales to assets ratio | x | 0.7 | 1.1 | 58.4% | |
| Return on assets | % | 6.7 | -0.1 | -5,467.5% | |
| Return on equity | % | 10.0 | -0.3 | -3,356.3% | |
| Return on capital | % | 10.0 | 0 | - | |
| Exports to sales | % | 32.8 | 5.7 | 574.9% | |
| Imports to sales | % | 0 | 6.5 | 0.0% | |
| Exports (fob) | Rs m | 49,883 | 270 | 18,461.4% | |
| Imports (cif) | Rs m | NA | 306 | 0.0% | |
| Fx inflow | Rs m | 51,691 | 375 | 13,799.0% | |
| Fx outflow | Rs m | 21,033 | 470 | 4,473.7% | |
| Net fx | Rs m | 30,658 | -96 | -32,085.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 14,628 | -8 | -180,587.7% | |
| From Investments | Rs m | -8,540 | -146 | 5,861.4% | |
| From Financial Activity | Rs m | -3,855 | 862 | -447.1% | |
| Net Cashflow | Rs m | 2,431 | 709 | 343.1% | |
Share Holding
| Indian Promoters | % | 16.0 | 0.0 | - | |
| Foreign collaborators | % | 20.8 | 75.0 | 27.7% | |
| Indian inst/Mut Fund | % | 12.2 | 0.3 | 4,066.7% | |
| FIIs | % | 23.7 | 15.7 | 151.0% | |
| ADR/GDR | % | 1.1 | 0.0 | - | |
| Free float | % | 26.2 | 9.1 | 287.9% | |
| Shareholders | 161,166 | 12,856 | 1,253.6% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: TTK HEALTHCARE ALEMBIC LTD WYETH LTD ELDER PHARMA SUVEN LIFE
Compare CIPLA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Tanks ahead of Election Results; Realty Stocks Plummet(Closing)
Indian share markets settled around 2% lower today following a sell-off in the global markets and due to uncertainty over the outcome of state assembly elections tomorrow.
Related Views on News
ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)
Nov 27, 2018 | Updated on Nov 27, 2018For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)
Nov 12, 2018 | Updated on Nov 12, 2018For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)
Nov 30, 2018Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.
4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)
Dec 3, 2018Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.
Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)
Nov 29, 2018Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?
Safety Beats Growth in 2018(Chart Of The Day)
Nov 30, 2018With the markets turning up, these are my top 7 stock picks.
Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)
Dec 5, 2018Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.
More|
| |
CIPLA SHARE PRICE
Dec 10, 2018 (Close)
TRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA - DIVIS LABORATORIES COMPARISON
COMPARE CIPLA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.